Danilo Rocco

Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients

Umberto Malapelle, Clara Mayo de-las-Casas, Danilo Rocco et al. · British Journal of Cancer · 2017 · 137 citations · Full text

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

Alessio Cortellini, Massimo Di Maïo, Olga Nigro et al. · Journal for ImmunoTherapy of Cancer · 2021 · 132 citations · Full text

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

Alessio Cortellini, Biagio Ricciuti, Marcello Tiseo et al. · Journal for ImmunoTherapy of Cancer · 2020 · 95 citations · Full text

Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients

Cirino Botta, Vito Barbieri, Domenico Ciliberto et al. · Cancer Biology & Therapy · 2013 · 92 citations · Full text

Inflammatory Lung Disease, Baseline Predicts, Lung Inflammation +18

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

Alessio Cortellini, Marcello Tiseo, Giuseppe Luigi Banna et al. · Cancer Immunology Immunotherapy · 2020 · 87 citations · Full text

Advanced Nsclc, Oncology, First-line Pembrolizumab Effectiveness +6